These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 35821755)

  • 1. Amikacin liposome inhalation suspension clinical benefit-risk assessment for refractory
    Marras TK; Hassan M; Mange KC; Ciesielska M; Murthy SD; Jumadilova Z; Chatterjee A
    ERJ Open Res; 2022 Jul; 8(3):. PubMed ID: 35821755
    [No Abstract]   [Full Text] [Related]  

  • 2. Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by
    Griffith DE; Eagle G; Thomson R; Aksamit TR; Hasegawa N; Morimoto K; Addrizzo-Harris DJ; O'Donnell AE; Marras TK; Flume PA; Loebinger MR; Morgan L; Codecasa LR; Hill AT; Ruoss SJ; Yim JJ; Ringshausen FC; Field SK; Philley JV; Wallace RJ; van Ingen J; Coulter C; Nezamis J; Winthrop KL;
    Am J Respir Crit Care Med; 2018 Dec; 198(12):1559-1569. PubMed ID: 30216086
    [No Abstract]   [Full Text] [Related]  

  • 3. Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use.
    Hoy SM
    Clin Drug Investig; 2021 Apr; 41(4):405-412. PubMed ID: 33723805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease.
    Shirley M
    Drugs; 2019 Apr; 79(5):555-562. PubMed ID: 30877642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amikacin Liposome Inhalation Suspension for
    Golia A; Mahmood BR; Fundora Y; Thornby KA; Chahine EB
    Sr Care Pharm; 2020 Apr; 35(4):162-170. PubMed ID: 32192565
    [No Abstract]   [Full Text] [Related]  

  • 6. Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Lung Disease: Sustainability and Durability of Culture Conversion and Safety of Long-term Exposure.
    Griffith DE; Thomson R; Flume PA; Aksamit TR; Field SK; Addrizzo-Harris DJ; Morimoto K; Hoefsloot W; Mange KC; Yuen DW; Ciesielska M; Wallace RJ; van Ingen J; Brown-Elliott BA; Coulter C; Winthrop KL;
    Chest; 2021 Sep; 160(3):831-842. PubMed ID: 33887244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amikacin liposome inhalation suspension as a treatment for patients with refractory mycobacterium avium complex lung infection.
    Zhang Y; Hill AT
    Expert Rev Respir Med; 2021 Jun; 15(6):737-744. PubMed ID: 34039231
    [No Abstract]   [Full Text] [Related]  

  • 8. Amikacin Liposome Inhalation Suspension as a Treatment Option for Refractory Nontuberculous Mycobacterial Lung Disease Caused by Mycobacterium avium Complex.
    Swenson C; Del Parigi A
    Mayo Clin Proc; 2020 Jan; 95(1):201-202. PubMed ID: 31902419
    [No Abstract]   [Full Text] [Related]  

  • 9. In reply-Amikacin Liposome Inhalation Suspension as a Treatment Option for Refractory Nontuberculous Mycobacterial Lung Disease Caused by Mycobacterium avium Complex.
    Shulha J
    Mayo Clin Proc; 2020 Jan; 95(1):202. PubMed ID: 31902420
    [No Abstract]   [Full Text] [Related]  

  • 10. A Case of Single-lung Transplant in a Patient with Mycobacterium avium Pulmonary Disease Successfully Treated with Amikacin Liposome Inhalation Suspension.
    Ozeki T; Higo H; Omori H; Mori S; Tanaka S; Makimoto G; Ninomiya K; Taniguchi A; Fujii M; Miyoshi K; Rai K; Ichihara E; Ohashi K; Sugimoto S; Hotta K; Tabata M; Toyooka S; Maeda Y; Miyahara N
    Intern Med; 2024 Sep; ():. PubMed ID: 39261070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laryngeal Injury Due to Amikacin Inhalation for Refractory Mycobacterium avium Complex Infection.
    Axiotakis LG; Enver N; Keating CL; Pitman MJ
    Chest; 2021 Apr; 159(4):e185-e187. PubMed ID: 34022015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis and Management of Drug-Induced Interstitial Lung Disease Associated with Amikacin Liposome Inhalation Suspension in Refractory
    Hashimoto K; Nii T; Sumitani H; Yokoyama M; Miyamoto S; Mihashi Y; Nagata Y; Matsuki T; Tsujino K; Miki K; Kida H
    Infect Drug Resist; 2023; 16():6629-6634. PubMed ID: 37840829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early-Phase Adverse Effects and Management of Liposomal Amikacin Inhalation for Refractory
    Morita A; Namkoong H; Yagi K; Asakura T; Hosoya M; Tanaka H; Lee H; Ogawa T; Kusumoto T; Azekawa S; Nakagawara K; Kamata H; Ishii M; Fukunaga K; Ozawa H; Hasegawa N
    Infect Drug Resist; 2022; 15():4001-4011. PubMed ID: 35924016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correction to: Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease.
    Shirley M
    Drugs; 2019 May; 79(7):791. PubMed ID: 30941606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nontuberculous mycobacterial lung disease caused by
    van Ingen J; Obradovic M; Hassan M; Lesher B; Hart E; Chatterjee A; Daley CL
    Expert Rev Respir Med; 2021 Nov; 15(11):1387-1401. PubMed ID: 34612115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correction to: Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use.
    Hoy SM
    Clin Drug Investig; 2021 Jun; 41(6):591. PubMed ID: 33880719
    [No Abstract]   [Full Text] [Related]  

  • 17. Real-World Outcomes of Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Pulmonary Disease.
    Kim BG; Kim SR; Jhun BW
    Tuberc Respir Dis (Seoul); 2024 Apr; 87(2):202-205. PubMed ID: 37726944
    [No Abstract]   [Full Text] [Related]  

  • 18. ALIS (Amikacin Liposome Inhalation Suspension): The Beginning of a Wonderland?
    Daley CL; Olivier KN
    Am J Respir Crit Care Med; 2018 Dec; 198(12):1473-1475. PubMed ID: 30365392
    [No Abstract]   [Full Text] [Related]  

  • 19. Amikacin Inhalation as Salvage Therapy for Refractory Nontuberculous Mycobacterial Lung Disease.
    Jhun BW; Yang B; Moon SM; Lee H; Park HY; Jeon K; Kwon OJ; Ahn J; Moon IJ; Shin SJ; Daley CL; Koh WJ
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29661870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Management of Respiratory Adverse Events Associated With Amikacin Liposome Inhalation Suspension: Results From a Patient Survey.
    Swenson C; Lapinel NC; Ali J
    Open Forum Infect Dis; 2020 Apr; 7(4):ofaa079. PubMed ID: 32322600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.